icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 48 Weeks After the End of Treatment From an Interim Analysis of a Randomized Phase 3 Study, MYR301
 
 
 
AASLD Nov 15-19, 2024
 
Soo Aleman1, Maurizia Brunetto2,3, Antje Blank4, Pietro Andreone5, Pavel Bogomolov6, Vladimir Chulanov7, Nina Mamonova8, Natalia Geyvandova9, Viacheslav Morozov10, Olga Sagalova11, Tatyana Stepanova12, Grace M Chee13, Dmitry Manuilov13, Sarah Arterburn13, Audrey H Lau13, Anu Osinusi13, Florence Christian-Cox13, Frank Duff13, Julian Schulze zur Wiesch14, Markus Cornberg15, Stefan Zeuzem16, Heiner Wedemeyer15, Pietro Lampertico17,18

1203241

1203242

1203243

1203244

1203245

1203246

1203247

1203248